Skip to main content
Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd. — Investor Relations & Filings

Ticker · ENLV ISIN · IL0011319527 TA Manufacturing
Open in API
Filings indexed 485 across all filing types
Latest filing 2025-03-03 Report Publication Anno…
Country IL Israel
Listing TA ENLV

About Enlivex Therapeutics Ltd.

https://enlivex.com/

Enlivex Therapeutics Ltd. is a clinical-stage macrophage reprogramming immunotherapy company. It is focused on developing Allocetra™, a universal, off-the-shelf cell therapy designed to treat immune system dysregulation. The therapy works by reprogramming macrophages to resolve hyper-inflammation. Enlivex is evaluating Allocetra™ in clinical trials for the treatment of multiple indications, including acute inflammatory diseases such as sepsis and chronic inflammatory conditions like osteoarthritis. The product candidate offers flexible administration options, including systemic intravenous infusion and targeted local injections.

Recent filings

Filing Released Lang Actions
Enlivex Announces Positive Interim Data – Statistically Significant 47.0% Durable and Persistent Pain Reduction At Six Months, in Patients with Moderate to Severe Knee Osteoarthritis
Report Publication Announcement Classification · 1% confidence The document is extremely short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *6k03032025_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). The presence of the Israel Securities Authority and Tel Aviv Stock Exchange context confirms it is a regulatory filing announcement.
2025-03-03 English
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
Regulatory Filings Classification · 1% confidence The document is explicitly titled 'Form 6-K' and is filed with the 'UNITED STATES SECURITIES AND EXCHANGE COMMISSION'. Form 6-K is the standard filing for a Foreign Private Issuer to report material information that is required to be disclosed to shareholders in their home country or exchange, or that is material to the company. This type of filing does not map directly to the specific US periodic reports (like 10-K or 10-Q) or specific event reports (like DEF 14A or DIRS). Since it is a mandatory regulatory filing that doesn't fit the other specific categories (like ER, CT, DIV, etc.), the most appropriate classification based on the provided definitions is the general regulatory fallback category, 'Regulatory Filings' (RNS). The content is an urgent statement regarding fraudulent news, which is material information disclosed via the 6-K mechanism.
2025-02-18 English
Enlivex Issues Urgent Statement on Fraudulent News Dissemination
Report Publication Announcement Classification · 1% confidence The document is very short (1765 characters) and explicitly states, "Attached hereto is a report on*6k* *180220256K_isa.pdf*". This structure indicates that the document itself is an announcement about the publication of another report (a Form 6-K, which is a general SEC filing for foreign private issuers, often used for material events). According to Rule 2, when a document is short and announces the availability of a report, it should be classified as a Report Publication Announcement (RPA). The presence of the Israel Securities Authority and Tel Aviv Stock Exchange context suggests it's a regulatory filing, but the primary function of this specific text is to announce the attached 6-K report.
2025-02-18 English
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Regulatory Filings Classification · 1% confidence The document explicitly identifies itself as a "Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934," which corresponds to a Form 6-K filing. Form 6-K filings are typically used by foreign private issuers to report material information to the SEC, often mirroring press releases or other material events. The content is a press release announcing regulatory authorization for a Phase I clinical trial. While it contains detailed information, the primary structure and context provided by the SEC header (Form 6-K) and the inclusion of a press release (Exhibit 99.1) strongly suggest this is a routine regulatory filing that doesn't fit the specific categories like ER (Earnings Release) or IR (Interim Report). Since Form 6-K is a general reporting mechanism for foreign private issuers, and the content is a specific announcement, the most appropriate general category among the provided options that covers miscellaneous regulatory announcements is 'Regulatory Filings' (RNS), although 'RPA' (Report Publication Announcement) could also be considered if it were just announcing the release of a major report. Given the SEC filing structure (Form 6-K) and the nature of the announcement (clinical trial update), RNS is the best fit as a catch-all for non-standard SEC reports that aren't 10-K, IR, or ER.
2024-12-11 English
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Report Publication Announcement Classification · 1% confidence The document is extremely short (1765 characters) and explicitly states, "Attached hereto is a report on *6k* *6K11122024_isa.pdf*". This structure indicates that the document itself is merely an announcement or cover page stating that a formal report (in this case, a 6-K filing, which is an SEC filing for foreign private issuers) is attached or published, rather than being the full content of the 6-K report. According to Rule 2, when a document is short and announces the publication of another report, it should be classified as a Report Publication Announcement (RPA).
2024-12-11 English
Form 6-K - Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis
Regulatory Filings Classification · 1% confidence The document explicitly states it is a 'Form 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934' for the month of December 2024. Form 6-K is used by foreign private issuers to report material information to the SEC, often mirroring the content of a press release. The core content is a press release announcing positive interim efficacy data from a clinical trial. This type of filing, which reports material, non-periodic information for a foreign private issuer, is generally classified under the broad 'Regulatory Filings' category (RNS) when a more specific SEC form code (like 10-K or DEF 14A) is not applicable, or if the content is primarily a press release furnished via 6-K. Since 'Form 6-K' is not an available code, and the content is a material announcement furnished as an exhibit to a regulatory filing, RNS (Regulatory Filings) is the most appropriate general classification for this SEC submission that isn't a standard periodic report or specific event filing listed.
2024-12-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.